Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bunkyo-ku
Clinical trial register · Japan

Clinical Trials in Bunkyo-ku, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals22 AbbVie14 Takeda11 Pfizer10 Bristol-Myers Squibb9
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Bunkyo-ku

98 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Kurume-shi, Sapporo, Kumamoto, Kyoto, Matsumoto-shi, Suita-shi, Bunkyo-ku, Shinjuku-ku
2027-11-23
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Sapporo, Yokohama, Suita, Bunkyo-ku, Fukuoka, Maebashi, Okayama
2027-02-03
Not yet open
Bayer
Phase 2
8
Nagoya, Yokohama, Toyonaka, Bunkyo-ku, Kyoto
2027-01-25
Recruiting
Kiminori Kimura, MD
Phase 2
7
Sapporo, Sendai, Osaka, Bunkyo-Ku
2026-10-01
Recruiting
Takeda
Phase 3
324
Chiba, Toon-shi, Kobe, Hitachi, Tsu, Miyazaki, Bunkyo-Ku, Chuo-shi
2026-09-10
Recruiting
Amgen
Phase 3
400
Bunkyo-ku
2026-08-28
Recruiting
Takeda
Phase 2
9
Nagoya, Maebashi, Tsu, Suita, Bunkyo-ku, Shinjuku-ku, Sumida-ku, Chūō
2026-07-14
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Nagoya, Gifu, Bunkyo Ku, Kodaira, Yonago
2026-06-03
Recruiting
AbbVie
Phase 1
30
Nagoya, Bunkyo-ku, Shinjuku-ku
2026-05-28
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Kamogawa, Sapporo, Kobe, Shiwa-Gun, Tsu, Bunkyo Ku, Bunkyo-ku, Chūō
2026-05-27
Recruiting
Takeda
Phase 3
300
Nagoya, Fukushima, Gifu, Fukuyama-shi, Amagasaki-shi, Mibu, Bunkyo-ku, Shinagawa-ku
2026-05-21
Not yet open
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2
17
Bunkyo-ku, Itabashi-ku, Shibuya-ku
2026-05-10
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Chikugo, Sapporo, Zentsujichó, Miyakonojō, Bunkyo-ku, Ōta-ku, Yokohama, Kanagawa
2026-04-07
Recruiting
Astellas Pharma Inc
Phase 1/2
84
Sendai, Bunkyo-ku, Toyama, Kyoto, Tokushima
2026-04-03
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Sagamihara, Kashihara, Bunkyo Ku
2026-03-24
Recruiting
Novartis Pharmaceuticals
Observational
30
Kurume, Osaka, Suita, Bunkyo Ku
2026-03-23
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Gifu, Kobe, Tsukuba, Kawasaki, Bunkyo-ku, Koto-ku, Ube, Kyoto
2026-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Kobe, Bunkyo Ku, Chiyoda-ku
2026-03-09
Recruiting
AbbVie
Phase 1
127
Bunkyo Ku, Koto-ku
2026-02-27
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Kashiwa, Matsuyama, Fukuoka, Kashihara-shi, Sakai, Suita, Bunkyo-ku, Koto
2026-02-17
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Kashiwa, Sendai, Hirakata, Nagaizumi-cho, Bunkyo-ku
2026-01-30
Recruiting
Bristol-Myers Squibb
Phase 3
166
Chikugo-Shi, Sapporo, Zentsujichó, Miyakonojō, Bunkyo-ku, Ōta-ku, Yokohama, Kanagawa
2026-01-29
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
Hiroshima, Asahikawa, Bunkyo-ku, Fuchu-shi, Setagaya-ku, Shinjuku-ku
2025-12-11
Recruiting
Bristol-Myers Squibb
Phase 3
650
Hadano, Kawasaki, Sakai, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Bunkyo-ku, Fukuoka, Okayama
2025-12-02
Active, closed
Novartis Pharmaceuticals
Phase 1
6
Nagoya, Kobe, Bunkyo Ku, Koto Ku
2025-11-26
Recruiting
AbbVie
Phase 2
180
Kashiwa-shi, Sunto-gun, Bunkyo Ku, Chuo-Ku, Wakayama
2025-11-25
Recruiting
Takeda
Phase 2
200
Nagoya, Sakura-shi, Nishi-ku, Tokyo, Bunkyo-ku
2025-11-03
Recruiting
Takeda
Phase 3
70
Kurume-shi, Bunkyo-ku, Setagaya-ku
2025-10-27
Recruiting
Bristol-Myers Squibb
Phase 3
424
Toyoake, Ichikawa, Iizuka, Kitakyushu-shi, Sapporo, Yokohama, Karatsu, Bunkyo-ku
2025-10-08
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Chikushino-shi, Kitakyushu, Kamakura, Sagamihara, Bunkyo Ku
2025-10-03
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Kawasaki, Bunkyo-ku, Koto-ku, Toyoma
2025-09-30
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Kashiwa, Sunto-gun, Bunkyo-ku, Koto, Fukuoka, Osaka
2025-08-19
Recruiting
AbbVie
Phase 1
135
Kashiwa-shi, Kumamoto, Mibu, Bunkyo-ku, Koto-ku
2025-08-07
Recruiting
Pfizer
Phase 3
400
Chiba, Kashiwa, Matsuyama, Otashi, Isehara, Yokohama, Suita, Bunkyo-ku
2025-08-05
Recruiting
AbbVie
Phase 2/3
854
Yokohama, Niigata, Takatsuki, Sunto-gun, Bunkyo-ku, Chuo-Ku
2025-08-03
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Sapporo, Yokohama, Bunkyo-ku, Shinjuku-ku, Chiba, Fukuoka, Okayama, Osaka
2025-07-14
Recruiting
Bristol-Myers Squibb
Phase 3
426
Hadano, Kawasaki, Sakai, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Bunkyo-ku, Fukuoka, Okayama
2025-07-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,000
Amagasaki-shi, Tomigusuku, Kawachi-Nagano, Kita-Ku, Bunkyo-ku, Saga
2025-06-25
Recruiting
Takeda
Phase 3
59
Nagoya, Kumamoto, Sendai, Kashihara, Higashi-Matsuyama, Ōtsu, Tokushima, Bunkyo-ku
2025-05-06
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
Shimotsuke-shi, Bunkyo-Ku, Chiba
2025-04-09
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Higashi-Matsuyama, Bunkyo-Ku, Kodaira
2025-04-01
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Chiba, Sapporo, Kobe, Sendai, Suita, Bunkyo Ku, Shinjuku-ku, Fukuoka
2025-03-13
Recruiting
Takeda
Phase 2
96
Fukuoka-Shi Hakata-Ku, Kurume-shi, Kohoku-ku, Yokohama-Shi, Kumamoto, Yodogawa-ku, Osaka-shi, Bunkyo-ku
2025-02-07
Recruiting
Pfizer
Phase 3
211
Bunkyo-ku
2025-01-22
Recruiting
Takeda
Phase 3
70
Kurume, Bunkyo-ku, Setagaya-Ku
2025-01-22
Active, closed
Pfizer
Phase 3
1,035
Nagoya, Otashi, Sapporo, Yokohama, Sakyo-ku, Sendai, Suita, Bunkyo-ku
2025-01-06
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Sapporo, Yokohama, Sendai, Suita, Izumo, Bunkyo-ku, Shinjuku-ku, Fukuoka
2024-12-17
By invitation
CoreTissue BioEngineering Inc.
Not applicable
64
Hirosaki, Hiroshima, Sapporo, Kobe, Bunkyo-ku, Shinjuku-ku
2024-11-25
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Sapporo, Sendai, Suita, Bunkyo-ku, Fukuoka, Ishikawa, Kyoto
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Nagoya, Toyoake, Yokohama, Iruma-gun, Bunkyo-ku, Shinjuku Ku, Toyama, Hiroshima
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Chiba, Sapporo, Kobe, Yokohama, Sendai, Suita, Izumo, Bunkyo Ku
2024-09-04
Active, closed
AbbVie
Phase 3
111
Kashiwa-shi, Kurume-shi, Sendai, Izumi-Shi, Saga, Saitama-shi, Bunkyo-ku, Fuchu-shi
2024-08-08
Active, closed
Pfizer
Observational
450
Kitakyushu-shi, Kurume-shi, Ebina, Sendai, Niigata, Osaka, Hamamatsu, Bunkyo-ku
2024-08-07
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
109
Sayama, Kawagoe, Yaizu, Bunkyo-Ku, Kodaira, Chiba, Fukuoka, Saga
2024-07-12
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo-ku, Chuo Ku, Fuchū, Itabashi-ku
2024-05-21
Active, closed
Bristol-Myers Squibb
Phase 2
310
Nagoya, Toride-Shi, Kurashiki-Shi, Hirakata-Shi, Osaka, Bunkyo-Ku, Hachioji-Shi, Setagaya-Ku
2024-03-20
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Matsumoto-shi, Iruma-gun, Bunkyo Ku
2024-02-28
Recruiting
Pfizer
Phase 3
492
Toyohashi, Matsuyama, Maebashi, Shibukawa, Kobe, Shiwa-gun Yahaba-cho, Bunkyo-ku, Koto
2024-02-08
Active, closed
Pfizer
Phase 3
394
Nagoya, Sendai, Sakai, Bunkyo-ku, Shinjuku-ku, Kofu
2024-01-19
Active, closed
Study of Tamibarotene in Patients With ADPKD
NCT06289998Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugTamibarotene
Rege Nephro Co., Ltd.
Phase 2
70
Kurume, Sapporo, Kamakura, Kawasaki, Kyoto, Bunkyo-ku, Minato-ku, Shinjukuku
2023-12-22
Active, closed
Bristol-Myers Squibb
Phase 3
190
Nagoya, Kashiwa, Matsuyama, Sapporo, Yokohama, Sendai, Bunkyo Ku, Yonago
2023-12-21
Active, closed
AbbVie
Phase 3
614
Nagoya, Sakai-shi, Suita-shi, Bunkyo-ku, Shinjuku-ku, Yamagata, Kofu
2023-12-19
Recruiting
AbbVie
Phase 3
110
Ōbu, Kashiwa-shi, Kurume-shi, Maebashi, Kumamoto, Izumi-Shi, Saitama-shi, Bunkyo-ku
2023-12-11
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Kitakyushu, Sapporo, Kamimashi-gun, Habikino, Takatsuki, Ōtsu, Izumo, Bunkyo-ku
2023-12-07
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
87
Nagoya, Kashiwa-shi, Kanazawa, Yokohama, Osaka, Hamamatsu, Bunkyo-ku, Koto-Ku
2023-12-06
Active, closed
AbbVie
Phase 3
122
Kashiwa-shi, Kurume-shi, Sapporo, Sendai, Izumi-Shi, Osaka, Saitama-shi, Bunkyo-ku
2023-11-06
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Nagoya, Kitakyushu, Sapporo, Yokohama, Kuwana, Sasebo, Kurashiki, Bunkyo Ku
2023-10-27
Recruiting
AbbVie
Phase 3
90
Kobe, Kawasaki-shi, Niigata, Takatsuki-shi, Bunkyo-ku
2023-10-02
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2/3
16
Chikushino-shi, Sendai, Nishihara, Suita, Bunkyo-ku, Minato-ku, Shinjuku-ku, Asahikawa
2023-08-01
Active, closed
AbbVie
Phase 3
1,014
Kitakyushu-shi, Sapporo, Sendai, Miyazaki, Okayama, Naha, Kawagoe, Bunkyo-ku
2023-07-25
Recruiting
Pfizer
Phase 3
318
Kitakyushu-shi, Kawasaki, Sendai, Okayama, Ōtsu, Bunkyo-ku, Shinjuku-ku, Ube
2023-05-20
Recruiting
Takeda
Phase 3
240
Kurume-Shi, Kumamoto, Hidaka, Bunkyo-Ku, Setagaya-Ku
2023-05-16
Recruiting
Takeda
Phase 2/3
500
Kurume-Shi, Kumamoto, Nagasaki, Osaka, Bunkyo-Ku, Nagakute
2023-04-05
Active, closed
Bayer
Phase 3
985
Sapporo, Kanazawa, Yokohama, Suita, Bunkyo-ku, Kyoto
2023-04-03
Active, closed
Pfizer
Phase 3
624
Nagoya, Chiba, Kashiwa, Sapporo, Yokohama, Suita, Ina-machi, Bunkyo-ku
2023-03-03
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Nagoya, Sapporo, Yokohama, Sendai, Bunkyo Ku, Bunkyo-ku, Chuo Ku, Fuchū
2023-03-02
Recruiting
Pfizer
Phase 2
36
Kashiwa, Nagareyama-shi, Maebashi, Nishinomiya, Ikoma, Saitama-shi, Shimotsuke, Bunkyo-ku
2022-12-16
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Nagoya, Kitakyushu, Sapporo, Yokohama, Kuwana, Sasebo, Kurashiki, Bunkyo Ku
2022-08-04
Active, closed
Tanabe Pharma Corporation
Phase 3
80
Yoshida-gun, Kanazawa, Kawasaki-shi, Bunkyo-ku
2022-07-20
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Osaka, Bunkyo Ku, Koto Ku
2022-07-07
Recruiting
Bristol-Myers Squibb
Phase 2/3
120
Ōbu, Kurume-shi, Komatsu, Yokohama, Takatsuki, Bunkyo-Ku, Setagaya-ku, Shinjuku-ku
2022-05-30
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Kashiwa-shi, Yoshida-gun, Fukushima, Isehara-shi, Nagasaki, Bunkyo-ku, Bunkyō City, Fukuoka
2022-02-28
Recruiting
Takeda
Phase 3
120
Kurume-Shi, Kumamoto, Bunkyo-Ku, Setagaya-Ku
2022-02-10
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 3
626
Kashiwa-shi, Yokohama, Osaki-shi, Suita-shi, Hidaka-shi, Ina-machi, Kitaadati-gun, Nagaizumi-Cho, Sunto-Gun, Bunkyo-ku
2021-11-05
Active, closed
Beeline Medicines Corporation
Phase 2
248
Chiba, Eiheiji-cho,Yoshida-gun, Kitakyushu, Fukushima, Sapporo, Kanazawa, Sendai, Bunkyo-ku
2021-10-11
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Nagoya, Sapporo, Kobe, Yokohama, Kumamoto, Suita, Kitaadachi-gun, Bunkyo Ku
2021-06-09
Active, closed
Celgene
Phase 3
313
Nagasaki, Sayama, Bunkyo-ku, Chūō, Aomori, Bunkyō City, Isehara City, Kanagawa, Kamakura
2021-02-25
Recruiting
PharmaEssentia Japan K.K.
Phase 3
67
Toon-shi, Tsu, Suita-shi, Bunkyo-ku, Shinjuku-ku, Chuo-shi
2021-01-19
Active, closed
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
NCT04499248Open-angle Glaucoma, Ocular Hypertension
AbbVie
Phase 1/2
100
Sagamihara-shi, Wako, Izumo-shi, Bunkyo-ku, Tama-shi, Chuo-shi, Fukuoka
2020-11-16
Active, closed
Bristol-Myers Squibb
Phase 1/2
31
Suwa, Bunkyo-ku, Chūō, Aomori, Bunkyō City, Fukuoka, Hitachi, Ibaraki, Isehara City, Kanagawa
2020-10-12
Active, closed
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847Myelodysplastic Syndrome, Acute Myeloid Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
170
Kashiwa, Bunkyo-ku, Yamagata
2020-08-07
Active, closed
AbbVie
Phase 1
85
Kamakura-shi, Osakasayama-shi, Suita-shi, Bunkyo-ku, Chuo-shi
2019-11-08
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Sapporo, Bunkyo Ku, Fukuoka
2019-06-26
Active, closed
AbbVie
Phase 1
124
Obu-shi, Kobe, Kagoshima, Kawasaki-shi, Sendai, Niigata, Bunkyo-ku
2019-06-24
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
DrugsZolbetuximab·Nab-paclitaxel·Gemcitabine
Astellas Pharma Global Development, Inc.
Phase 2
393
Nagoya, Kashiwa, Sapporo, Yokohama, Kashihara, Bunkyo-ku, Chuo-ku, Koto-ku
2019-03-15
Active, closed
Eisai Co., Ltd.
Phase 1
140
Kashiwa, Sapporo, Nishinomiya, Yokohama, Hidaka, Bunkyo-ku, Chuo-ku, Koto-ku
2017-08-18
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Sakura-shi, Higashiku, Maebashi, Kida-gun, Yokohama, Sayama, Bunkyo-ku, Koutou-ku
2016-12-22
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Nagoya, Sapporo, Isehara, Suita, Bunkyo Ku, Fukuoka, Osaka
2015-03-05
Rows per page Showing 1–98 of 98
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/bunkyo-ku

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 98 of those studies with a site in Bunkyo-ku.

How many clinical trials are recruiting in Bunkyo-ku?

50 of the 98 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 4 have not yet opened recruitment, 42 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bunkyo-ku), 98 studies
PhaseStudiesRecruitingShare
Phase 3512952%
Phase 221921.4%
Phase 1939.2%
Phase 1/2737.1%
Phase 2/3555.1%
Observational212%
Phase 4202%
Not applicable101%

Most active sponsors

Lead sponsors with the most studies (Bunkyo-ku)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals228
AbbVie147
Takeda1111
Pfizer106
Bristol-Myers Squibb96
Astellas Pharma Global Development, Inc.53
Bayer20
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company20
Ono Pharmaceutical Co., Ltd.20
Sanofi20
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.